360+ NCFB patients engaged through advocacy partnerships on our last Phase 2 rescue study, delivered on time, at a third of the expected acquisition cost.

NCFB clinical trial recruitment built on advocacy-led education, backed by digital awareness campaigns and physician referral networks. We deliver enrollment-ready patients to your sites, not referrals that create coordinator work.

Talk to our NCFB teamSee how it works →
1/3
Of expected patient acquisition cost
On Time
Planned enrollment timeline achieved
25+
NCFB advocacy partnerships in our network
Multi-national
Program delivered across multiple countries

Understanding Non-Cystic Fibrosis Bronchiectasis as a Clinical Trial Indication

Non-cystic fibrosis bronchiectasis (NCFB) is a chronic respiratory disease in which the airways become permanently widened and scarred, leading to persistent cough, sputum, and repeated lung infections. It is distinct from bronchiectasis caused by cystic fibrosis, and it is widely underdiagnosed: symptoms overlap with COPD, asthma, and chronic bronchitis, so many patients live for years with recurrent chest infections before a CT scan confirms the diagnosis. Prevalence rises sharply with age and is higher in women, and care is split across pulmonology and primary care, so eligible patients are scattered rather than concentrated.

For sponsors, that makes NCFB a hard indication to enroll. The eligible population is hidden behind delayed and mistaken diagnoses, patients and caregivers frequently do not know their condition has a name or that trials exist, and awareness and education are central to whether anyone comes forward. Broad advertising reaches volume but rarely reaches the diagnosed, motivated NCFB patient efficiently, so recruitment depends on trusted advocacy relationships and patient education, not a single tactic.

Leapcure recruits NCFB patients through advocacy partnerships built for a chronic, underdiagnosed respiratory community, backed by digital awareness campaigns and physician referral networks. On a completed multi-national Phase 2 NCFB rescue program, this advocacy-led, education-first approach engaged 360+ qualified NCFB patients within four months, achieved the planned enrollment timeline, and cut patient acquisition cost to a third of expectations. That NCFB result sits within a broader respiratory portfolio: in Leapcure's completed IPF and pulmonary fibrosis programs, a separate indication, the team engaged 15,000+ patients, assigned 589 to sites, and delivered 77 enrollments across a 50+ site network supported by 25+ PF advocacy partnerships. The IPF/PF figures belong to that program and are never presented as NCFB numbers.

The Challenge

NCFB trial recruitment demands more than reach. It demands finding a hidden, dispersed population and educating patients until they enroll.

Underdiagnosis hides eligible NCFB patients

NCFB symptoms overlap with COPD, asthma, and chronic bronchitis, so many patients are treated for the wrong condition for years before a CT scan confirms bronchiectasis. The diagnosed, eligible pool is smaller and more hidden than prevalence figures suggest, and site-only recruitment reaches only a fraction of it.

Leapcure's advocacy-led model reaches diagnosed NCFB patients through the communities they trust. On a completed multi-national Phase 2 NCFB rescue program, this engaged 360+ qualified patients within four months.

NCFB recruitment is education-first

Many NCFB patients and caregivers do not know their condition has a name, how it differs from cystic fibrosis, or that trials are an option. Without education, interest never converts to enrollment, and referrals that skip this step create coordinator work at the site.

Leapcure pairs advocacy partnerships with digital awareness campaigns and physician referral networks, delivering enrollment-ready patients to sites rather than raw referrals.

The eligible population is dispersed across regions

NCFB patients are scattered across pulmonology and primary care rather than concentrated at a few centers, and enrollment often has to work across multiple countries at once. When one market lags, timelines slip.

Leapcure delivered its NCFB rescue program across multiple countries and achieved the planned enrollment timeline, rebalancing channels by region.

Sponsors need proof an agency can deliver on time and under cost

A rescue engagement leaves no room for a slow ramp. Sponsors need evidence that a recruitment agency can convert reach into qualified patients quickly, hold the timeline, and do it for less than broad advertising costs.

On a completed Phase 2 NCFB rescue study, Leapcure engaged 360+ qualified patients within four months, achieved the planned enrollment timeline, and cut patient acquisition cost to a third of expectations.

Three Steps. One Advocacy-Led, Education-First Strategy for Your NCFB Trial.

Leapcure starts from advocacy partnerships built for the NCFB community, reinforces them with digital awareness and physician referral, and educates every patient through to the site, mapped to your protocol, your sites, and your timeline.

1

Activate advocacy partnerships built for the NCFB community

Leapcure begins from 25+ NCFB advocacy partnerships, including national lung-health organizations and dedicated bronchiectasis communities. Content is co-developed with these partners and grounded in patient education, so research reaches NCFB patients through voices they already trust rather than as an unsolicited pitch.

2

Layer digital awareness, physician referral, and pre-screening

Advocacy is reinforced with digital awareness campaigns and physician referral networks that surface diagnosed patients across pulmonology and primary care. Every patient is educated about NCFB and the study and pre-screened against the protocol's criteria before site referral, so sites receive enrollment-ready candidates, not referrals that create coordinator work.

3

Optimize by region to hold the timeline and control cost

Channel performance and site engagement are tracked across markets and rebalanced by referral quality and site capacity. On the completed NCFB rescue program, this discipline achieved the planned enrollment timeline and cut patient acquisition cost to a third of expectations.

Phase 2 NCFB Rescue Program, Completed. 360+ Patients Engaged in Four Months, On Time, at a Third of Expected Cost.

Challenge Context

Indication

Non-cystic fibrosis bronchiectasis, Phase 2 rescue program

Sponsor

Anonymized (no sponsor or study name disclosed)

Challenge

A rescue engagement with no room for a slow ramp, an underdiagnosed and dispersed patient population, and a multi-national footprint requiring education-led outreach across markets.

Channels deployed

Advocacy partnerships built for the NCFB community, reinforced by digital awareness campaigns and physician referral networks, with education-first patient support.

Results & Metrics

Patients engaged

360+ qualified NCFB patients engaged through advocacy partnerships within four months.

Timeline

Achieved the planned enrollment timeline.

Cost efficiency

Patient acquisition cost cut to a third of expectations. Acquisition cost varies by protocol, phase, site selection, and channel mix.

Reach

Delivered across multiple countries (multi-national); a specific country count is not disclosed.

Advocacy network

Drawn from 25+ NCFB advocacy partnerships in Leapcure's network.

Four Channels. Built for NCFB. Active Before Your Trial Opens.

Leapcure reaches NCFB patients through advocacy community outreach, digital awareness campaigns, physician referral and patient support, and answer-engine visibility delivered to your trial.

Channel 1: NCFB Advocacy Network

  • •25+ NCFB advocacy partnerships, including the American Lung Association, the Respiratory Health Association of Metropolitan Chicago, Bronchiectasis and NTM 360°, and Bronchiectasis USA, plus grassroots and patient-led NCFB communities.
  • •Content is co-developed with advocacy partners and grounded in patient education, so research reaches patients through sources they already trust.
  • •These partnerships are active and co-developed, not list purchases.

Channel 2: Digital Awareness Campaigns

  • •Search and social awareness campaigns designed for a widely underdiagnosed condition, targeted by geography, eligibility, and site proximity.
  • •Messaging is education-first, helping patients recognize NCFB and understand how it differs from cystic fibrosis before they consider a trial.
  • •Digital is mapped to site capacity so referrals stay matched to where sites can screen.

Channel 3: Physician Referral and Patient Success

  • •Physician referral networks surface diagnosed NCFB patients across pulmonology and primary care.
  • •A Patient Success Team educates each patient and caregiver, confirms eligibility against the protocol, and prepares them for the site visit.
  • •This support is why sites receive enrollment-ready patients rather than referrals that create coordinator work.

Channel 4: Answer-Engine and AI-Search Visibility

  • •NCFB patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may be eligible for. Leapcure makes your trial's information genuinely retrievable by these engines.
  • •That means crawlable, server-rendered content with clear answer passages, unique first-party data, cited sources, and presence in the respiratory communities AI engines actually cite. It is good content structure plus real authority, not schema tricks or AI markup.
  • •As AI search grows as a patient-discovery path, this channel compounds over the life of your study.

Built on Trusted Relationships in the NCFB Community

Leapcure's NCFB advocacy partnerships are active, named, and co-developed, not list purchases. 25+ partnerships span national organizations, regional groups, and patient-led bronchiectasis communities; the four below are named anchors.

American Lung Association

National lung-health authority and credibility anchor for respiratory recruitment.

Respiratory Health Association of Metropolitan Chicago

Regional respiratory-health organization extending reach into local patient communities.

Bronchiectasis and NTM 360°

Dedicated bronchiectasis and NTM education initiative reaching diagnosed patients and caregivers.

Bronchiectasis USA

Patient-focused bronchiectasis community and trusted peer voice for NCFB patients.

Living with non-cystic fibrosis bronchiectasis? A clinical trial may be an option.

If you are living with non-cystic fibrosis bronchiectasis, a clinical trial may give you access to investigational treatments that are not yet widely available. We know that constant cough, repeated infections, and years of uncertain answers are exhausting, and that researching trial options on top of that is a lot. Leapcure's team offers step-by-step support, answers your questions, and includes your family or caregivers wherever that helps.

See if an NCFB trial may be right for you
Leapcure kangaroo mascot

Leapcure has completed a multi-national Phase 2 non-cystic fibrosis bronchiectasis rescue program, engaging 360+ qualified NCFB patients through advocacy partnerships within four months, achieving the planned enrollment timeline, and cutting patient acquisition cost to a third of expectations. We deploy advocacy partnerships, digital awareness campaigns, physician referral networks, and education-first Patient Success support adapted to your protocol, and we can mobilize within 48 hours of program launch.

Talk to our NCFB team